U.S., Dec. 19 -- ClinicalTrials.gov registry received information related to the study (NCT07292142) titled 'FMT in Triple Negative Breast Cancer Guided by ctDNA' on Nov. 19.
Brief Summary: Triple-negative breast cancer (TNBC) is an aggressive form of breast cancer, usually treated with chemotherapy and an immune checkpoint blockade (ICB) in the pre-operative or neoadjuvant phase. However, about 35% of tumors do not respond fully to this therapy, and patient prognosis is poor. Recent exciting data from our group and others suggest that the alteration of the gut microbiome via fecal microbiota transplantation (FMT) markedly affects the response to ICB in melanoma1-3. The investigators propose to test the safety and feasibility of altering t...